Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Recurrence 2Neoplasm Metastasis 2Delirium 2

Interventions

Cisplatin 13Paclitaxel 11Cyclophosphamide 11Doxorubicin 10Magnetic Resonance Spectroscopy 9Prednisone 8Gemcitabine 8Docetaxel 8Specimen Handling 7Oxaliplatin 7Carboplatin 7Vincristine 6Etoposide 6Capecitabine 6pembrolizumab 5Rituximab 5Radiotherapy 5Leucovorin 5Cytarabine 5Bevacizumab 5atezolizumab 4Trastuzumab 4Platinum 4Nivolumab 4Fluorouracil 4Dexamethasone 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Haloperidol × Clear all
NCT03021486 2026-03-18

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
70 enrolled 20 charts

Delirium, Neoplasm Metastasis, Recurrence

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡